

**In the Claims**

Please cancel claims 1-9, 18-20, and 24-68 without prejudice or disclaimer of the subject matter thereof.

Please amend claims 10 and 23, and add claims 69-94 as follows:

**Claims:**

- 1 – 9. (canceled).
10. (currently amended) A recombinant polypeptide comprising one or more, but not all regions of a full-length human pleiotrophin receptor protein.
11. (original) The polypeptide of claim 10, wherein the one or more regions are selected from the group consisting of an extracellular domain, an intracellular domain, a pleiotrophin binding site, a growth factor binding site, a mitogenic factor binding site, an antigenic domain, tyrosine kinase, a heparin binding site, a glycosylated domain, a non-glycosylated domain, a signaling domain, a functional domain, a conserved domain, a transmembrane domain, and combinations thereof.
12. (original) The polypeptide of claim 10, which is antigenic.
13. (original) The polypeptide of claim 10, which contains anti-angiogenic activity.
14. (original) The polypeptide of claim 10, which induces apoptosis.
15. (original) The polypeptide of claim 10, which contains anti-motogenic activity.
16. (original) The polypeptide of claim 10, which contains anti-mitogenic activity.
17. (original) The polypeptide of claim 10, which contains anti-cell proliferative activity.
- 18 – 20. (canceled).
21. (original) A composition comprising the polypeptide of claim 10.
22. (original) The composition of claim 21, wherein the polypeptide contains the pleiotrophin-binding site.
23. (currently amended) ~~The A composition comprising of claim 22 wherein the polypeptide is a peptido-mimetic of a pleiotrophin binding site of a human ALK protein.~~  
A composition comprising of claim 22 wherein the polypeptide is a peptido-mimetic of a pleiotrophin binding site of a human ALK protein.
- 24 – 68. (canceled).
69. (new) A recombinant polypeptide comprising:  
the pleiotrophin receptor binding site of a human ALK protein; and

one or more, but not all other regions of the human ALK protein.

70. (new) The polypeptide of claim 69, which is antigenic.
71. (new) The polypeptide of claim 69, which contains anti-angiogenic activity.
72. (new) The polypeptide of claim 69, which induces apoptosis.
73. (new) The polypeptide of claim 69, which contains anti-motogenic activity.
74. (new) The polypeptide of claim 69, which contains anti-mitogenic activity.
75. (new) The polypeptide of claim 69, which contains anti-cell proliferative activity.
76. (new) A composition comprising the polypeptide of claim 69.
77. (new) The polypeptide of claim 69, wherein the one or more regions are selected from the group consisting of an extracellular domain, an intracellular domain, a growth factor binding site, a mitogenic factor binding site, an antigenic domain, tyrosine kinase, a heparin binding site, a glycosylated domain, a non-glycosylated domain, a signaling domain, a functional domain, a conserved domain, a transmembrane domain, and combinations thereof.
78. (new) A recombinant polypeptide comprising:
  - a pleiotrophin receptor binding site homologous to the pleiotrophin receptor binding site of human ALK; and
  - one or more, but not all other regions of a full-length human ALK protein excluding the pleiotrophin receptor binding site.
79. (new) The polypeptide of claim 78, wherein the one or more regions are selected from the group consisting of an extracellular domain, an intracellular domain, a growth factor binding site, a mitogenic factor binding site, an antigenic domain, tyrosine kinase, a heparin binding site, a glycosylated domain, a non-glycosylated domain, a signaling domain, a functional domain, a conserved domain, a transmembrane domain, and combinations thereof.
80. (new) The polypeptide of claim 78, wherein the pleiotrophin binding site is homologous to amino acid sequence positions 368-447 of human ALK.
81. (new) The polypeptide of claim 78, wherein the pleiotrophin binding site is homologous to amino acid sequence positions 391-401 of human ALK.
82. (new) The polypeptide of claim 78, which is antigenic.
83. (new) The polypeptide of claim 78, which contains anti-angiogenic activity.

84. (new) The polypeptide of claim 78, which induces apoptosis.
85. (new) The polypeptide of claim 78, which contains anti-motogenic activity.
86. (new) The polypeptide of claim 78, which contains anti-mitogenic activity.
87. (new) The polypeptide of claim 78, which contains anti-cell proliferative activity.
88. (new) A composition comprising the polypeptide of claim 78.
89. (new) A recombinant polypeptide comprising two or more copies of a pleiotrophin receptor binding site homologous to the pleiotrophin receptor binding site of human ALK.
90. (new) The polypeptide of claim 89, wherein each pleiotrophin binding site is homologous to amino acid sequence positions 368-447 of human ALK.
91. (new) The polypeptide of claim 89, wherein each pleiotrophin binding site is homologous to amino acid sequence positions 391-401 of human ALK.
92. (new) A polypeptide that consists essentially of a pleiotrophin receptor binding site.
93. (new) The polypeptide of claim 92, wherein the pleiotrophin receptor binding site comprises amino acid sequence positions 368-447 of human ALK.
94. (new) The polypeptide of claim 92, wherein the pleiotrophin receptor binding site comprises amino acid sequence positions 391-401 of human ALK.